Conflict of Interest Disclosures: Dr Eggermont reported being the study chair of the EORTC 18071 phase 3 clinical trial
of ipilimumab therapy vs placebo in patients with stage III melanoma and receiving
personal fees from Actelion, Agenus, Amgen, Bayer, BioInvent, Bristol-Myers Squibb,
CatalYm, Celldex, Gilead Sciences, GlaxoSmithKline, HalioDx, Incyte, IO Biotech, ISA
Pharmaceuticals, MedImmune, Merck Sharpe & Dohme, Nektar, Novartis, Pfizer, Polynoma,
Regeneron Pharmaceuticals, Sanofi, and SkylineDx and owning equity in SkylineDx outside
the submitted work. Dr Kicinski reported receiving grants from Merck during the conduct
of the study. Dr Blank reported receiving grants from Bristol-Myers Squibb, NanoString
Technologies, and Novartis and personal fees from AstraZeneca, Bristol-Myers Squibb,
GenMab, GlaxoSmithKline, Lilly, Merck Sharpe & Dohme, NanoString Technologies, Novartis,
Pfizer, Pierre Fabre, and Roche during the conduct of the study. Dr Mandala reported
receiving grants from Genentech/Roche and Novartis and serving as an advisor for Bristol-Myers
Squibb, Merck Sharpe & Dohme, Novartis, and Pierre Fabre outside the submitted work.
Dr Long reported receiving personal fees from Aduro, Amgen, Array BioPharma, Bristol-Myers
Squibb, Merck, Novartis, OncoSec, Pierre Fabre, and Roche outside the submitted work.
Dr Atkinson reported receiving personal fees, speaking fees, and/or travel support
from and/or serving on the advisory board of Bristol-Myers Squibb, Merck Serono, Merck
Sharpe & Dohme, Novartis, OncoSec, Pierre Fabre, and Roche outside the submitted work.
Dr Dalle reported receiving grants from Bristol-Myers Squibb and Merck Sharpe & Dohme
outside the submitted work. Dr Haydon reported receiving personal fees from Merck
outside the submitted work. Dr Carlino reported receiving personal fees from Amgen,
Bristol-Myers Squibb, IDEAYA Biosciences, Merck Sharpe & Dohme, Novartis, and Roche
outside the submitted work. Dr Sandhu reported receiving grants from Amgen, AstraZeneca,
Bristol-Myers Squibb, Endocyte, and Merck Sharp & Dohme outside the submitted work.
Dr Larkin reported receiving grants from Achilles Therapeutics, AVEO Pharmaceuticals,
Bristol-Myers Squibb, Covance, Genentech/Roche, Immunocore, Merck Sharpe & Dohme,
Nektar, Novartis, Pharmacyclics, and Pfizer and personal fees from Achilles Therapeutics,
AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Covance, Eisai, EUSA Pharma,
Genentech/Roche, GlaxoSmithKline, Immunocore, Imugene, Incyte, iOnctura, Ipsen, Kymab,
Merck Serono, Merck Sharpe & Dohme, Nektar, Novartis, Pfizer, Pierre Fabre, Secarna
Pharmaceuticals, and Vitaccess during the conduct of the study. Dr Puig reported receiving
patient fees for Merck Sharpe & Dohme during the conduct of the study and receiving
grants from Almirall, Castle Biosciences, Leo Pharma, MelaGenix, and Novartis, personal
fees and nonfinancial support from Almirall, Amgen, Bristol-Myers Squibb, ISDIN, La
Roche-Posay, Leo Pharma, Lilly, Novartis, Pierre Fabre, Roche, and Sanofi, and patient
fees for Biofrontera, Bristol-Myers Squibb, Philogen, and Regeneron Pharmaceuticals
outside the submitted work. Dr Ascierto reported receiving grants and research funds
from Array BioPharma, Bristol-Myers Squibb, and Genentech/Roche and receiving personal
fees for serving as an advisor for 4SC, Array BioPharma, AstraZeneca, Bristol-Myers
Squibb, Genentech/Roche Genmab, Idera Pharmaceutials, Immunocore, Incyte, MedImmune,
Merck Serono, Merck Sharp & Dohme, NewLink Genetics, Novartis, Pierre Fabre, Sandoz,
Sanofi, Sun Pharma, Syndax Pharmaceuticals, and Ultimovacs outside the submitted work.
Dr Rutkowski reported receiving personal fees from Amgen, Bristol-Myers Squibb, Merck
Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, and Roche outside the submitted work.
Dr Schadendorf reported receiving personal fees and nonfinancial support from Merck
Sharp & Dohme during the conduct of the study and receiving grants from Bristol-Myers
Squibb and personal fees and nonfinancial support from 4SC, Array BioPharma, Boehringer
Ingelheim, Bristol-Myers Squibb, Immunocore, InflaRx, NeraCare, Novartis, Philogen,
Pierre Fabre, Regeneron Pharmaceuticals, Roche, Sandoz-Hexal, Sanofi, Sun Pharma,
and Ultimovacs outside the submitted work. Dr Koornstra reported receiving grants
from Bristol-Myers Squibb and Roche and personal fees from AstraZeneca, Bristol-Myers
Squibb, Merck Sharp & Dohme, Novartis, and Pierre Fabre outside the submitted work.
Dr Hernandez-Aya reported receiving grants from Merck during the conduct of the study
and receiving grants from Amgen, Bristol-Myers Squibb, Corvus Pharmaceuticals, Immunocore,
MedImmune, Merck Serono, Merck Sharp & Dohme, Polynoma, Roche, and Takeda, personal
fees from Bristol-Myers Squibb, and speaking fees and travel support from Regeneron
Pharmaceuticals and Sanofi outside the submitted work. Dr Di Giacomo reported receiving
personal fees from Merck Sharp & Dohme during the conduct of the study and receiving
personal fees from Bristol-Myers Squibb, Incyte, and Pierre Fabre outside the submitted
work. Dr van den Eertwegh reported receiving personal fees from Amgen, Bristol-Myers
Squibb, Merck Sharp & Dohme, Novartis, and Roche outside the submitted work. Dr Grob
reported receiving personal fees from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme,
Novartis, Pfizer, Pierre Fabre, and Roche outside the submitted work. Dr Gutzmer reported
receiving grants from Johnson & Johnson and Pfizer and personal fees and nonfinancial
support from 4SC, Almirall, Amgen, AstraZeneca, Bristol-Myers Squibb, Incyte, Merck
Serono, Merck Sharpe & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Sun Pharma,
and Takeda outside the submitted work. Dr Jamal reported receiving grants and patient
fees from Merck Sharpe & Dohme during the conduct of the study and receiving grants
from Bristol-Myers Squibb, patient fees for Array BioPharma, Astellas, AstraZeneca,
Bristol-Myers Squibb, the Canadian Cancer Trials Group, GlaxoSmithKline, Hoffman-La
Roche, MedImmune, Merck Canada, Novartis Canada, Pfizer, and Genentech/Quintiles/Roche,
and serving as an advisor for Bristol-Myers Squibb, Merck Sharpe & Dohme, and Novartis
outside the submitted work. Dr Lorigan reported receiving patient fees for the European
Organisation for Research and Treatment of Cancer during the conduct of the study
and receiving grants from Bristol-Myers Squibb and personal fees, speaking fees, and/or
travel support from or serving as an advisor for Amgen, Bristol-Myers Squibb, Incyte,
Merck, NeraCare, Novartis, and Pierre Fabre outside the submitted work. Dr Ibrahim
reported owning financial shares in GlaxoSmithKline and Merck outside the submitted
work. Dr van Akkooi reported receiving grants from 4SC, Amgen, Bristol-Myers Squibb,
Merck Sharpe & Dohme, Novartis, and Pfizer outside the submitted work. Dr Robert reported
receiving personal fees from Merck Sharpe & Dohme during the conduct of the study
and receiving personal fees from Amgen, Bristol-Myers Squibb, Novartis, Pierre Fabre,
Roche, and Sanofi outside the submitted work. Dr Suciu reported receiving grants from
Merck during the conduct of the study. No other disclosures were reported.